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Abstract
Purpose—Studies of smoking and risk of non-Hodgkin lymphoma (NHL) have yielded
inconsistent results, possibly due to subtype heterogeneity and/or genetic variation impacting the
metabolism of tobacco-derived carcinogens, including substrates of the N-acetyltransferase
enzymes NAT1 and NAT2.
Methods—We conducted a pooled analysis of 5,026 NHL cases and 4,630 controls from seven
case–control studies in the international lymphoma epidemiology consortium to examine
associations between smoking, variation in the N-acetyltransferase genes NAT1 and NAT2, and
risk of NHL subtypes. Smoking data were harmonized across studies, and genetic variants in
NAT1 and NAT2 were used to infer acetylation phenotype of the NAT1 and NAT2 enzymes,
respectively. Pooled odds ratios (ORs) and 95 % confidence intervals (95 % CIs) for risk of NHL
and subtypes were calculated using joint fixed effects unconditional logistic regression models.
Results—Current smoking was associated with a significant 30 % increased risk of follicular
lymphoma (n = 1,176) but not NHL overall or other NHL subtypes. The association was similar
among NAT2 slow (OR 1.36; 95 % CI 1.07–1.75) and intermediate/rapid (OR 1.27; 95 % CI
0.95–1.69) acetylators (pinteraction = 0.82) and also did not differ by NAT1*10 allelotype. Neither
NAT2 phenotype nor NAT1*10 allelotype was associated with risk of NHL overall or NHL
subtypes.
Conclusion—The current findings provide further evidence for a modest association between
current smoking and follicular lymphoma risk and suggest that this association may not be
influenced by variation in the N-acetyltransferase enzymes.
Keywords
Non-Hodgkin lymphoma; Gene environment interaction; Cigarette smoking; N-acetyltransferase;
Follicular lymphoma
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Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignant neoplasms that
arise from lymphoid tissues at various stages of differentiation. Other than the importance of
immune dysregulation and certain infections, the etiology of NHL is not well understood
[1]. Numerous studies examining the role of tobacco smoking in NHL risk have yielded
inconsistent results, although these studies were generally underpowered to investigate NHL
subtype-specific associations [2]. Previously, a large pooled analysis in the international
lymphoma epidemiology consortium (InterLymph) found that current smokers had a
statistically significant 30 % increased risk of follicular lymphoma compared with never
smokers [3], while a multicenter case–control study in Europe did not find a significant
association [4]. Given this potential modest subtype-specific association, further evidence is
needed to elucidate a possible role for smoking in risk of follicular lymphoma and other
NHL subtypes.
Cigarettes contain numerous carcinogenic compounds, many of which are activated or
deactivated by xenobiotic-metabolizing enzymes [5]. The N-acetyltransferase enzymes,
NAT1 and NAT2, metabolize aromatic and heterocyclic amines and can lead to
detoxification or activation of tobacco-derived carcinogens [6]. The activity of these
enzymes can vary between individuals, and the relative activity can be predicted via
determination of genotypes for specific single nucleotide polymorphisms (SNPs) in the
NAT1 and NAT2 genes. These genetic variations with known functional consequences for
NAT1 or NAT2 activity have been demonstrated conclusively to modify risk for bladder
cancer, particularly among cigarette smokers [7], indicating a mechanistic role for aromatic
or heterocyclic amines such as those found in cigarettes. Differing susceptibility due to
genetic variation in metabolic enzymes such as the N-acetyltransferases could account for
the inconsistent associations observed between smoking and NHL risk. The few previous
studies that have examined the combined effects of NAT1 or NAT2 genetic variants and
smoking on risk of NHL have not had sufficient sample size to investigate NHL subtypes
[8–10].
We conducted a pooled analysis in seven case–control studies from the InterLymph
consortium to examine associations between smoking, NAT1 or NAT2 variability, and risk
of NHL and NHL subtypes. These new analyses included more than 3,700 NHL cases and
3,400 controls that were not examined in the earlier InterLymph smoking analysis [3].
Furthermore, an interaction between smoking and NAT variability on risk of NHL or NHL




Seven case–control studies with available data on cigarette smoking status and NAT1 or
NAT2 genotypes were identified through the InterLymph consortium. The seven studies
included four from the United States (Nebraska [10], National Cancer Institute-Surveillance
Epidemiology End Results (NCI-SEER) [11], Yale University/Connecticut (Yale) [12], and
University of California at San Francisco (UCSF2) [13]), two from Europe (Scandinavian
Lymphoma Etiology (SCALE) [14], and EpiLymph [15]), and one from Australia (New
South Wales [16]). Genotype data for NAT1 were available for four studies (New South
Wales, Nebraska, NCI-SEER, Yale), whereas NAT2 data were available for six studies (all
but New South Wales). Methodological details of the individual studies have been published
previously [10–16] and are summarized in Table 1. Analyses were restricted to non-
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Hispanic white participants. Each participating study obtained informed consent from
participants and approval from local human subjects committees.
Exposure assessment
Each study obtained detailed information on smoking behaviors, demographics, and
potential confounders via in-person or telephone interviews. Each then provided original,
individual-level de-identified data to a central data-coordinating center for harmonization of
variables according to pre-specified rules. Smoking status was classified as never (never
smoked more than 100 cigarettes or never smoked regularly for more than 6 months), former
(quit at least 12 months before cancer diagnosis for cases or interview for controls), or
current (currently smoking or quit in the prior 12 months). Other smoking variables
harmonized from individual study data included frequency, duration, total pack-years, age at
start of smoking, and years since quitting for former smokers. Potential confounders
included age (<50, 50–59, 60–69, 70+), sex, socioeconomic status (low, medium, and high
based on education for all studies except New South Wales, which grouped a deprivation
indicator from census data into tertiles), and history of alcohol consumption (drinker, non-
drinker, missing; not available for UCSF2 and SCALE).
Genotyping and phenotype assignment
Genotype data were collected for four NAT1 (rs15561, rs1057126, rs4987076, and
rs13249533) and six NAT2 (rs1208, rs1041983, rs1799929, rs1799930, rs1799931, and
rs1801280) SNPs. Specific NAT1 and NAT2 SNPs were selected to infer NAT1 allelotype
(*3, *4, *10, *11, *11A, *11B, or *14A) and NAT2 acetylation activity (phenotype: slow,
intermediate, or rapid acetylation), as described previously [9, 17, 18]. Genotyping was
conducted by the individual studies and utilized Taqman (New South Wales [19], NCI-
SEER [9], Yale [8], UCSF2 [20]), Illumina GoldenGate (Epilymph [21]), Sequenom
(SCALE [22]), or PCR–RFLP (Nebraska [10]) methodology. Not all SCALE participants
had sufficient genotype data for accurate phenotype inference, so we included only the 72 %
of participants with NAT2 phenotype inferred with high confidence based on sufficient
genotype data. No participants in the UCSF2 study had sufficient data on the six SNP panel
to infer NAT2 phenotype. We thus included the 43 % of UCSF2 participants who had data
from a genomewide association study [20] for the tag SNP rs1495741, which has been
shown to predict NAT2 phenotype with high accuracy in populations of European descent
[23]. Only non-Hispanic white participants were included in the analyses, and the
distribution of inferred NAT2 phenotypes for UCSF2 was similar to that observed for the
other studies (Table 2). For both SCALE and UCSF2, distributions of smoking variables and
potential confounders among controls were similar between included participants and those
excluded due to insufficient genotype data (not shown).
Case ascertainment and classification
Cases of incident, histologically confirmed NHL (excluding plasma cell neoplasms) were
identified, and NHL subtypes were grouped according to the World Health Organization
(WHO) classification [24] using InterLymph Pathology Working Group guidelines [25].
Statistical methods
Pooled odds ratios (ORs) and 95 % confidence intervals (95 % CIs) were computed as
estimates of relative risk of NHL in joint fixed effects unconditional logistic regression
models, with NHL subtypes analyzed using polytomous models. Heterogeneity by study was
investigated to determine suitability of the fixed effects models. For both pooled and study-
specific estimates, multivariable models included age group and sex, as these were matching
factors for most studies. All models included adjustment for study center using the 16
Gibson et al. Page 5













centers within the seven participating studies. Additional adjustment for socioeconomic
status or alcohol consumption did not alter risk estimates. Wald χ2 tests with a
multiplicative interaction term between the factor of interest and study were employed with
all models to test for heterogeneity by study or study center. Likelihood ratio tests yielded
similar results in all analyses. We first separately examined main effects of smoking status
and NAT1 or NAT2 variation on risk of NHL and NHL subtypes. Investigation of NAT1
compared participants having one or two copies of the NAT1*10 allele with those having no
copies of the NAT1*10 allele, as has been done in previous studies of NAT1 variation and
cancer risk [8, 9]. Evidence suggests that the NAT1*10 and NAT1*11 allelotypes are
associated with increased NAT1 acetylation activity, so we also examined NAT1
phenotypes inferred from the presence (rapid or intermediate acetylation) or absence (slow
acetylation) of these alleles [26]. NAT2 comparisons were based on phenotypes assigned
from genotype data as described [18]. We then investigated the associations between
smoking status and NHL and its subtypes, stratified by NAT2 phenotype or NAT1
allelotype. Statistical interaction was assessed as a multiplicative cross-product term for
smoking status and NAT1 allelotype or NAT2 phenotype in multivariable models. Statistical
analyses were performed using SAS version 9.1 (SAS Institute, Inc., Cary, NC, USA).
Results
In a pooled analysis of original data for 5,026 NHL cases and 4,630 controls from seven
case–control studies (Table 2), current cigarette smoking was associated with a significantly
increased risk of follicular lymphoma (n = 1,176; OR 1.34; 95 % CI 1.12–1.59 compared to
never smoking) but not NHL overall or any other NHL subtype (Table 3). Notably, the
association remained (OR 1.30; 95 % CI 1.06–1.60) when the analysis was restricted to the
four studies (Nebraska, Epilymph, SCALE, and UCSF2; n = 3,752 NHL cases with 796
follicular lymphoma cases; 3,400 controls) that were not included in the previous
InterLymph smoking analysis [3]. Former smoking was not associated with follicular
lymphoma risk. Among current smokers, risk was increased for those with greater intensity
(≥10 vs. <10 cigarettes/day: OR 1.61, 95 % CI 1.09–2.40), duration (>15 vs. ≤15 years: OR
3.55, 95 % CI 1.80–6.98), or pack-years (≥10 vs. <10 pack-years: OR 2.01; 95 % CI 1.26–
3.19) of exposure, although there was not a significant linear dose-response.
We were able to infer NAT2 phenotypes for 4,421 NHL cases (968 follicular lymphoma
cases) and 4,095 controls, and NAT1 allelotypes for 1,528 NHL cases (455 follicular
lymphoma cases) and 1,586 controls. Among the subgroups with available NAT2 or NAT1
data, associations between current smoking and risk of follicular lymphoma, NHL, and other
NHL subtypes were similar to those observed in the entire study population (data not
shown). Inferred NAT2 phenotype was not associated with follicular lymphoma risk (Table
4), and stratification by NAT2 phenotype revealed similar positive associations between
current smoking and follicular lymphoma risk among slow (OR 1.36; 95 % CI 1.07–1.75)
and intermediate and rapid (OR 1.27; 95 % CI 0.95–1.69) acetylators (pinteraction = 0.82).
Similarly, neither the presence of the NAT1*10 allele (Table 4) nor the inferred rapid NAT1
phenotype (data not shown) had a significant impact on the smoking-follicular lymphoma
association (pinteraction = 0.32 and 0.84, respectively).
Analyses of associations between smoking and overall NHL risk were null in the pooled
data (Table 3) and in the individual studies (Tables S1 and S2). Similarly, neither NAT2
phenotype nor NAT1*10 allelotype was associated with risk of NHL overall or NHL
subtypes. There were also no significant associations with individual NAT2 or NAT1 SNPs,
although there was a suggestive inverse association between having minor alleles for
rs1799930 and risk of follicular lymphoma (OR 0.95; 95 % CI 0.89–1.01, assuming an
additive model). Stratified analyses investigated whether NAT2 phenotype or NAT1*10
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allelotype would affect the null associations between current smoking and risk of NHL or
subtypes, but results were generally similar among different NAT2 phenotypes or NAT1
allelotypes (Table S3). However, a significant interaction based on a small number of cases
(<15 per stratum) was observed between NAT1*10 allelotype and ever smoking for mantle
cell lymphoma (OR 1.29; CI 0.60–2.78 for no NAT1*10 alleles; OR 0.34; CI 0.12–0.92 for
at least one NAT1*10 allele; pinteraction = 0.03). No significant heterogeneity of results by
study was found for any of the pooled analyses.
Discussion
In this pooled analysis of 9,656 participants from seven NHL case–control studies in the
United States, Europe, and Australia, current smoking was associated with a significantly
increased risk of follicular lymphoma. This result confirms the association identified in a
previous InterLymph smoking pooled analysis [3], with 796 (68 %) of the 1,176 follicular
lymphoma cases in this study having not been included in the previous study. Although we
did not observe a strong linear dose-response with intensity or duration of exposure,
categorical analyses demonstrated increased follicular lymphoma risk among heavier
smokers and individuals who smoked for a longer period. In addition, our study showed that
the association between smoking and follicular lymphoma was not significantly modified by
acetylation status, as measured by NAT2 phenotype or NAT1*10 allelotype. This finding
suggests that NAT1 or NAT2 substrates in cigarette smoke are not prominently involved in
follicular lymphoma carcinogenesis, but enzyme activity was not measured directly and
some role for these substrates remains possible. Genetic variations in other carcinogen-
metabolizing pathways could play a role as well. The cytochrome P-450 (CYP) enzymes
have been associated with risk of smoking-related cancers [27], although studies of CYP
variation and NHL risk have not generally yielded strong associations [28–32].
While case–control studies support a positive association between current smoking and
follicular lymphoma, results from prospective cohort studies have been mixed [33–37].
Some studies observed positive associations [34, 36], but two large cohort studies reported
an inverse association with current smoking based on 257 and 161 follicular lymphoma
cases [33, 37]. The authors of these studies suggest the observed protective associations are
implausible and likely due to confounding or chance, but the observations remain
unexplained. Strong dose–response associations have generally not been observed for case–
control or cohort studies. One study reported a stronger association between smoking and
NHL risk when women with exposure to passive smoking were excluded from the reference
category [34]. The associations we observed for follicular lymphoma may be attenuated by
exposure of never smokers to passive smoking, but data on passive smoke exposure were
not available.
In contrast to some previous reports based on much smaller samples [8, 9], we did not
observe any associations between NAT2 inferred phenotypes or NAT1 allelotypes and risk
of NHL or NHL subtypes. Pooling of data from multiple studies yielded 8,516 participants
for NAT2 analyses and 3,114 participants for NAT1 analyses, with no indication of
significant heterogeneity across studies. These pooled results, representing the largest
examination of NAT1 and NAT2 genetic variability and NHL risk yet reported, do not
support an association between inferred NAT1 allelotype or NAT2 phenotype and risk of
NHL or subtypes. The inferred rapid acetylation phenotype was relatively rare (6 % of
cases), and misclassification of phenotype is possible when inferred from genotypes [38], so
further study may be warranted.
This large pooled analysis enabled examination of associations between smoking and NHL
subtypes stratified by NAT1 or NAT2 status that was not possible in individual studies.
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However, even with pooling the power for stratified examinations of rare subtypes was low.
We report an interaction between NAT1*10 allelotype and ever smoking for risk of mantle
cell lymphoma, but given the small number of cases and large number of comparisons, this
finding may be attributed to chance. The use of original data allowed for harmonization of
exposures across studies, and a central coordinating center facilitated accurate pooling and
harmonization. Classification of NHL subtypes may be a source of variability, which we
addressed by using a single group of pathologists and epidemiologists to review the subtype
classifications. Given the lack of association observed for all other subtypes, any
misclassification of follicular lymphomas would be expected to attenuate the observed
association with current smoking. Genotyping platforms varied across studies, and we
excluded some participants from the UCSF2 and SCALE studies due to insufficient
genotype data, but genotype methodology and availability were unlikely to be associated
with smoking and thus were unlikely to introduce bias. NAT2 phenotypes were inferred for
UCSF2 participants using the tag SNP rs1495741; the distribution of the resulting
phenotypes was similar to that in the other studies, and UCSF2 results were not materially
different from those of the pooled analyses.
The current findings provide further evidence supporting a modest association between
current smoking and follicular lymphoma risk, and they suggest that this association may
not be strongly influenced by established variation in the N-acetyltransferase genes. Further
research is warranted to fully understand the association between smoking and follicular
lymphoma, particularly given the lack of linear dose–response associations and inconsistent
reports in prospective cohort studies [33–37].
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Table 4
Associations of NAT2 phenotype and NAT1 allelotype and risk of follicular lymphoma in the pooled study
populations and associations of smoking status with risk of follicular lymphoma stratified by NAT2 phenotype
and by NAT1 allelotype
Follicular lymphoma
Cases/controls OR (95 % CI)
NAT2 phenotypea,b
   Slow 543/2,366 1.00
   Intermediate 371/1,507 1.06 (0.91–1.23)
   Rapid 54/222 1.08 (0.79–1.48)
   Rapid/int 425/1,729 1.06 (0.92–1.23)
NAT2 slow
   Never smoking 246/1,056 1.00
   Former smoking 159/840 0.86 (0.69–1.08)
   Current smoking 138/470 1.36 (1.07–1.75)
NAT2 intermediate/rapid
   Never smoking 182/780 1.00
   Former smoking 148/605 1.07 (0.83–1.38)
   Current smoking 95/344 1.27 (0.95–1.69)
pinteraction 0.82
NAT1 allelotypec
   *Any/*any 295/1,040 1.00
   *Any/*10 139/484 1.00 (0.79–1.26)
   *10/*10 21/62 1.14 (0.68–1.92)
   At least one *10 160/546 1.02 (0.81–1.27)
NAT1*any/*any
   Never smoking 141/495 1.00
   Former smoking 98/383 0.95 (0.71–1.28)
   Current smoking 56/162 1.11 (0.77–1.61)
At least one NAT1*10 allele
   Never smoking 0/246 1.00
   Former smoking 54/225 0.82 (0.54–1.24)
   Current smoking 36/75 1.53 (0.93–2.51)
pinteraction 0.32
a
NAT2 phenotype inferred as slow, intermediate, or rapid acetylation based on genotype data for six NAT2 SNPs
b
NAT2 phenotype inferred based on genotype data for tag SNP rs1495741 for UCSF2 participants
c
NAT1 allelotype inferred as NAT1*10 or NAT1*any (*any includes *3,*4,*11,*11A,*14A) based on genotype data for four NAT1 SNPs
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